NeoGenomics, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $201.7M | $186.7M | $190.2M | $187.8M | $181.3M | $168.0M | $172.0M | $167.8M |
| Cost of Revenue | $109.8M | $105.8M | $106.8M | $107.4M | $104.1M | $94.8M | $94.7M | $92.9M |
| Gross Profit | $91.9M | $80.9M | $83.3M | $80.4M | $77.3M | $73.2M | $77.3M | $74.9M |
| Gross Margin | 45.6% | 43.3% | 43.8% | 42.8% | 42.6% | 43.6% | 44.9% | 44.6% |
| Operating Expenses | ||||||||
| Research & Development | $10.8M | $9.5M | $9.2M | $8.7M | $9.0M | $10.2M | $8.0M | $7.7M |
| SG&A Expense | $63.6M | $65.7M | $63.5M | $69.9M | $71.7M | $68.2M | $63.6M | $67.0M |
| Operating Income | $-9.8M | $-18.2M | $-13.4M | $-27.0M | $-47.6M | $-27.8M | $-18.4M | $-21.2M |
| Operating Margin | -4.8% | -9.8% | -7.1% | -14.4% | -26.3% | -16.6% | -10.7% | -12.6% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $1.8M | $-17.6M | $-12.4M | $-26.4M | $-45.8M | $-25.7M | $-16.1M | $-17.8M |
| Income Tax Expense | $-412.0K | $-472.0K | $-2.5M | $740.0K | $-724.0K | $266.0K | $-804.0K | $-150.0K |
| Net Income | $2.2M | $-17.1M | $-9.9M | $-27.1M | $-45.1M | $-25.9M | $-15.3M | $-17.7M |
| Net Margin | 1.1% | -9.2% | -5.2% | -14.4% | -24.9% | -15.4% | -8.9% | -10.5% |
| EPS (Basic) | $0.02 | $-0.13 | $-0.08 | $-0.21 | $-0.35 | $-0.20 | $-0.12 | $-0.14 |
| EPS (Diluted) | $0.02 | $-0.13 | $-0.08 | $-0.21 | $-0.35 | $-0.20 | $-0.12 | $-0.14 |
| Shares Outstanding (Basic) | 129.6M | 129.2M | 128.1M | 128.4M | 127.9M | 127.4M | 126.7M | 127.0M |
| Shares Outstanding (Diluted) | 130.8M | 129.2M | 128.1M | 128.4M | 127.9M | 127.4M | 126.7M | 127.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |